The stem cell niche as a pharmaceutical target for prevention of skeletal metastases

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 187-193

  Chirgwin, John M ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Anti resorptive agents; Bone metastases; Bone anabolic agents; Breast cancer; Endosteal niche; Hematopoietic niche; Mesenchymal cell niche; Prostate cancer; Stem cell niche

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; PARATHYROID HORMONE[1-34];

ARTICLE; BONE METASTASIS; CANCER GROWTH; CANCER STEM CELL; CELL HOMING; DRUG EFFECT; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; IN VIVO STUDY; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; STEM CELL NICHE; TUMOR MICROENVIRONMENT; VALIDATION PROCESS;

EID: 84857748339     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800228797     Document Type: Article

References (73)

1. Coleman, R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. CancerTreat. Rev., 2001, 27(3), 165-176.
2. Tubiana-Hulin, M. Incidence, prevalence and distribution of bone metastases. Bone, 1991, 12(Suppl 1), S9-S10.
3. Galasko, C.S. Mechanisms of lytic and blastic metastatic disease of bone. Clin. Orthop. Relat. Res., 1982, 169, 20-27.
4. Sturge, J.; Caley, M.P.; Waxman, J. Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat. Rev. Clin. Oncol., 2011, 8(6), 357-368.
5. Santini, D.; Galluzzo, S.; Zoccoli, A.; Pantano, F.; Fratto, ME.; Vincenzi, B.; Lombardi, L.; Gucciardino, C.; Silvestris, N.; Riva, E.; Rizzo, S.; Russo, A.; Maiello, E.; Colucci, G.; Tonini, G. New molecular targets in bone metastases. Cancer Treat. Rev., 2010, 36(Suppl 3), S6-S10.
6. Kingsley, L.A.; Fournier, P.G.; Chirgwin, J.M.; Guise, T.A. Molecular biology of bone metastasis. Mol. Cancer Ther., 2007, 6(10), 2609-2617.
7. Mohammad, K.S.; Fournier P.G.; Guise, T.A.; Chirgwin, J.M. Agents targeting prostate cancer bone metastasis. Anticancer Agents Med. Chem., 2009, 9(10), 1079-1088.
8. Meads, M.B.; Hazlehurst, L.A.; Dalton, W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res., 2008, 14(9), 2519-2526.
9. Hauschka, P.V.; Mavrakos, A.E.; Iafrati, M.D.; Doleman, S.E.; Klagsbrun, M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. J. Biol. Chem., 1986, 261(27), 12665-12674.
10. Guise, T.A. Bone loss and fracture risk associated with cancer therapy. Oncologist, 2006, 11(10), 1121-1131.
11. Schneider, A.; Kalikin, L.M.; Mattos, A.C.; Keller, E.T.; Allen, M.J.; Pienta, K.J.; McCauley, L.K. Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology, 2005, 146(4), 1727-1736.
12. Bonewald, L.F. The amazing osteocyte. J. Bone Miner. Res., 2011, 26(2), 229-238.
13. Coleman, R.E.; McCloskey, E.V. Bisphosphonates in oncology. Bone, 2011, 49(1), 71-76.
14. Body, J.J. New developments for treatment and prevention of bone metastases. Curr. Opin. Oncol., 2011, 23(4), 338-342.
15. Calvi, L.M.; Adams, G.B.; Weibrecht, K.W.; Weber, J.M.; Olson, D.P.; Knight, M.C.; Martin, R.P.; Schipani, E.; Divieti, P.; Bringhurst, F.R.; Milner, L.A.; Kronenberg, H.M.; Scadden, D.T. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature, 2003, 425(6960), 841-846.
16. Wang, J.; Loberg, R.; Taichman, R.S. The pivotal role of CXCL12 (SDF-1)/CXCR4 axis in bone metastasis. Cancer Metastasis Rev., 2006, 25(4), 573-587.
17. Hirbe, A.C.; Morgan, E.A.; Weilbaecher, K.N.; The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr. Pharm. Des., 2010, 16(11), 1284-1290.
18. Fowler, J.A.; Edwards, C.M.; Croucher, P.I. Tumor-host cell interactions in the bone disease of myeloma. Bone, 2011, 48(1), 121-128.
19. Roodman, G.D. Osteoblast function in myeloma. Bone, 2011, 48(1), 135-140.
20. Iwasaki, H.; Suda, T. Cancer stem cells and their niche. Cancer Sci., 2009, 100(7), 1166-1172.
21. Colmone, A.; Amorim, M.; Pontier, A.L.; Wang, S.; Jablonski, E.; Sipkins, D.A. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science, 2008, 322(5909), 1861-1865.
22. LaBarge, M.A. The difficulty of targeting cancer stem cell niches. Clin. Cancer Res., 2010, 16(12), 3121-3129.
23. Lin, H.; Balic, M.; Zheng, S.; Datar, R.; Cote, R.J. Disseminated and circulating tumor cells: Role in effective cancer management. Crit. Rev. Oncol. Hematol., 2011, 77(1), 1-11.
24. Liekens, S.; Schols, D.; Hatse, S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Des., 2010, 16(35), 3903-3920.
25. Shiozawa, Y.; Pedersen, E.A.; Havens, A.M.; Jung, Y.; Mishra, A.; Joseph, J.; Kim, J.K.; Patel, L.R.; Ying, C.; Ziegler, A.M.; Pienta, M.J.; Song, J.; Wang, J.; Loberg, R.D.; Krebsbach, P.H.; Pienta, K.J.; Taichman, R.S. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J. Clin. Invest., 2011, 121(4), 1298-1312.
26. Kuhn, N.Z.; Tuan, R.S. Regulation of stemness and stem cell niche of mesenchymal stem cells: implications in tumorigenesis and metastasis. J. Cell Physiol., 2010, 222(2), 268-277.
27. Shibue, T.; Weinberg, R.A. Metastatic colonization: settlement, adaptation and propagation of tumor cells in a foreign tissue environment. Semin. Cancer Biol., 2011, 21(2), 99-106.
28. Psaila, B.; Kaplan, R.N.; Port, E.R.; Lyden, D. Priming the 'soil' for breast cancer metastasis: the pre-metastatic niche. Breast Dis., 2006-2007, 26, 65-74.
29. Thorpe, M.P.; Valentine, R.J.; Moulton, C.J.; Wagoner Johnson, A.J.; Evans, E.M.; Layman, D.K. Breast tumors induced by Nmethyl- N-nitrosourea are damaging to bone strength, structure, and mineralization in the absence of metastasis in rats. J. Bone Miner. Res., 2011, 26(4), 769-776.
30. Liao, J.; McCauley, L.K. Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev., 2006, 25(4), 559-571.
31. Lymperi, S.; Ersek, A.; Ferraro, F.; Dazzi, F.; Horwood, N.J. Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood, 2011, 117(5), 1540-1549.
32. Todaro, M.; D'Asaro, M.; Caccamo, N.; Iovino, F.; Francipane, M.G.; Meraviglia, S.; Orlando, V.; La Mendola, C.; Gulotta, G.; Salerno, A.; Dieli, F.; Stassi, G. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J. Immunol., 2009, 182(11), 7287-7296.
33. Canalis, E.; Giustina, A.; Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med., 2007, 357(9), 905-916.
34. Gomes, R.R., Jr.; Buttke, P.; Paul, E.M.; Sikes, R.A. Osteosclerotic prostate cancer metastasis to murine bone are enhanced with increased bone formation. Clin. Exp. Metastasis., 2009, 26(7), 641-651.
35. Pennisi, A.; Ling, W.; Li, X.; Khan, S.; Wang, Y.; Barlogie, B.; Shaughnessy, J.D., Jr.; Yaccoby, S. Consequences of daily administered parathyroid hormone on myeloma growth, bone disease, and molecular profiling of whole myelomatous bone. PLoS One, 2010, 5, e15233.
36. Vallet, S.; Smith, M.R.; Raje, N. Novel bone-targeted strategies in oncology. Clin. Cancer Res., 2010, 16(16), 4084-4093.
37. Glaspy, J.A. Erythropoietin in cancer patients. Annu. Rev. Med., 2009, 60, 181-192.
38. Lee, A.S.; Kim, D.H.; Lee, J.E.; Jung, Y.J.; Kang, K.P.; Lee, S.; Park, S.K.; Kwak, J.Y.; Lee, S.Y.; Lim, S.T.; Sung, M.J.; Yoon, S.R.; Kim, W. Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis. Cancer Res., 2011, 71(13), 4506-4517.
39. Hadland, B.K.; Longmore, G.D. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms. J. Clin. Oncol., 2009, 27(25), 4217-4226.
40. Soltanoff, C.S.; Yang, S.; Chen, W.; Li, Y.P. Signaling networks that control the lineage commitment and differentiation of bone cells. Crit. Rev. Eukaryot. Gene Expr., 2009, 19(1), 1-46.
41. Bethel, M.; Srour, E.F.; Kacena, M.A. Hematopoietic cell regulation of osteoblast proliferation and differentiation. Curr. Osteoporos. Rep., 2011, 9(2), 96-102.
42. Mohammad, K.S.; Chirgwin, J.M.; Guise, T.A. Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol. Biol., 2008, 455, 37-50.
43. Winquist, R.J.; Furey, B.F.; Boucher, D.M. Cancer stem cells as the relevant biomass for drug discovery. Curr. Opin. Pharmacol., 2010, 10(4), 385-390.
44. Woods, N.B; Parker, A.S.; Moraghebi, R.; Lutz, M.K.; Firth, A.L.; Brennand, K.J.; Berggren, W.T.; Raya, A.; Belmonte, J.C.; Gage, F.H.; Verma, I.M. Efficient Generation of Hematopoietic Precursors and Progenitors from Human Pluripotent Stem Cell Lines. Stem Cells, 2011, 29(7), 1158-1164.
45. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat. Rev. Clin. Oncol., 2011, 8(2), 97-106.
46. Yao, H.; Ashihara, E.; Maekawa, T. Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin. Ther. Targets, 2011, 15(7), 873-887.
47. Weber, J.M.; Calvi, L.M. Notch signaling and the bone marrow hematopoietic stem cell niche. Bone, 2010, 46(2), 281-285.
48. Krause, U.; Harris, S.; Green, A.; Ylostalo, J.; Zeitouni, S.; Lee, N.; Gregory, C.A. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. Proc. Natl. Acad. Sci. U S A., 2010, 107(9), 4147-4152.
49. Suda, T.; Arai, F. Wnt signaling in the niche. Cell, 2008, 132(5), 729-730.
50. Sethi, N.; Dai, X.; Winter, C.G.; Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell, 2011, 19(2), 192-205.
51. Xing, F.; Okuda, H.; Watabe, M.; Kobayashi, A.; Pai, S.K.; Liu, W.; Pandey, P.R.; Fukuda, K.; Hirota, S.; Sugai, T.; Wakabayshi, G.; Koeda, K.; Kashiwaba, M.; Suzuki, K.; Chiba, T.; Endo, M.; Mo, Y.Y.; Watabe, K. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene, 2011, 30(39), 4075-4086.
52. Takahashi-Yanaga, F.; Sasaguri, T. Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: inhibitors of the Wnt/beta-catenin signaling pathway as novel anticancer drugs. J. Pharmacol. Sci., 2009(2), 109, 179-183.
53. Peinado, H.; Lavotshkin, S.; Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. Semin. Cancer Biol., 2011, 21(2), 139-146.
54. Sterling, J.A.; Guelcher, S.A. Bone structural components regulating sites of tumor metastasis. Curr. Osteoporos. Rep., 2011, 9(2), 89-95.
55. Langley, R.R.; Fidler, I.J. The seed and soil hypothesis revisited- the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer, 2011, 128(11), 2527-2535.
56. John, A.; Tuszynski, G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol. Oncol. Res., 2001, 7(1), 14-23.
57. Fong, J.E.; Le Nihouannen, D.; Komarova, S.V. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase. J. Biol. Chem., 2010, 285(41), 31427-31434.
58. Theman, T.A.; Collins, M.T. The role of the calcium-sensing receptor in bone biology and pathophysiology. Curr. Pharm. Biotechnol., 2009, 10(3), 289-301.
59. Brown, E.M. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR). Biochem. Pharmacol., 2010, 80(3), 297-307.
60. Prevarskaya, N.; Zhang, L.; Barritt, G. TRP channels in cancer. Biochim. Biophys. Acta, 2007, 1772(8), 937-946.
61. Nakamura, S.; Matsumoto, T.; Sasaki, J.; Egusa, H.; Lee, K.Y.; Nakano, T.; Sohmura, T.; Nakahira, A. Effect of calcium ion concentrations on osteogenic differentiation and hematopoietic stem cell niche-related protein expression in osteoblasts. Tissue Eng. Part A., 2010, 16(8), 2467-2473.
62. Holzer, P. Transient receptor potential (TRP) channels as drug targets for diseases of the digestive system. Pharmacol. Ther., 2011, 131(1), 142-170.
63. Hori, M.; Shimizu, Y.; Fukumoto, S. Minireview: fibroblast growth factor 23 in phosphate homeostasis and bone metabolism. Endocrinology, 2011, 152(1), 4-10.
64. Yin, J.J.; Mohammad, K.S.; Käkönen, S.M.; Harris, S.; Wu-Wong, J.R.; Wessale, J.L.; Padley, R.J.; Garrett, I.R.; Chirgwin, J.M.; Guise, T.A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. U S A., 2003, 100(19), 10954-10959.
65. Havens, A.M.; Pedersen, E.A.; Shiozawa, Y.; Ying, C.; Jung, Y.; Sun, Y.; Neeley, C.; Wang, J.; Mehra, R.; Keller, E.T.; McCauley, L.K.; Loberg, R.D.; Pienta, K.J.; Taichman, R.S. An in vivo mouse model for human prostate cancer metastasis. Neoplasia, 2008, 10(4), 371-380.
66. So, A.I.; Bowden, M.; Gleave, M. Effect of time of castration and tumour volume on time to androgen-independent recurrence in Shionogi tumours. B.J.U. Int., 2004, 93(6), 845-850.
67. Kelavkar, U.P.; Hutzley, J.; Dhir, R.; Kim, P.; Allen, K.G.; McHugh, K. Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. Neoplasia, 2006, 8(2), 112-124.
68. Jenkins, D.E.; Yu, S.F.; Hornig, Y.S.; Purchio, T.; Contag, P.R. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin. Exp. Metastasis, 2003, 20(8), 745-756.
69. Akslen, L.A.; Hove, L.M.; Hartveit, F. Metastatic distribution in malignant melanoma. A 30-year autopsy study. Invasion Metastasis, 1987, 7(5), 253-263.
70. Orita, Y.; Sugitani, I.; Matsuura, M.; Ushijima, M.; Tsukahara, K.; Fujimoto, Y.; Kawabata, K. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma. Surgery, 2010, 147(3), 424-431.
71. Kume, H.; Kakutani, S.; Yamada, Y.; Shinohara, M.; Tominaga, T.; Suzuki, M.; Fujimura, T.; Fukuhara, H.; Enomoto, Y.; Nishimatsu, H.; Homma, Y. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J. Urol., 2011, 185(5), 1611-1614.
72. Langer, C.; Hirsh, V. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer, 2010, 67(1), 4-11.
73. Laubach, J.; Richardson, P.; Anderson, K. Multiple myeloma. Annu. Rev. Med., 2011, 62, 249-264.